Table 1.
A summary of the consensus statements based on tumor histology and stage.
| Low Grade Glioma | 1st Line | • Vinblastine monotherapy (13) |
| 2nd Line | • Targeted inhibitor if MAPK alteration identified (14, 15), otherwise VCR/Carboplatin (16) | |
| High Grade Glioma | • Chemotherapy/radiation per ACNS0423 (17) | |
| DIPG | • Focal radiation | |
| Infant Medulloblastoma | AR | • Chemotherapy per 99703 (18) |
| HR | • Chemotherapy per 99703 (18) with additional IT chemotherapy | |
| Childhood Medulloblastoma | AR | • Radiation/chemotherapy per ACNS0331 with boost to tumor bed |
| HR | • Radiation/chemotherapy per ACNS0332 Regimen A with boost to tumor bed | |
| Ependymoma | Localized | • Focal radiation (19) |
| Craniopharyngioma | • Intracystic interferon (20) | |
| ATRT | • Chemotherapy per 99703 (18) +/− maintenance chemotherapy, avoid/delay radiation | |
| Germinoma | Localized | • Chemotherapy per ACNS1123 Stratum 2 with WVI ± boost to tumor |
| Disseminated | • Chemotherapy per ACNS1123 Stratum 2 with craniospinal radiation | |
| NGGCT | Localized | • SIOP CNS GCT-96 (21) or ACNS0122 (22) with radiation to tumor bed |
| Disseminated | • SIOP CNS GCT 96 (21) or ACNS0122 (22) with craniospinal radiation |
AR, average risk; ATRT, Atypical teratoid rhabdoid tumor; DIPG, diffuse intrinsic pontine glioma; HR, high risk; IT, intrathecal; VCR, vincristine NGGCT, non-germinomatous germ cell tumor; TMZ, temozolomide.